← Back to Clinical Trials
RecruitingPhase 1NCT02359825

Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

Trial Parameters

ConditionPeripheral Nerve Injury
SponsorVanderbilt University Medical Center
Study TypeINTERVENTIONAL
PhasePhase 1
Enrollment18
SexALL
Min Age18 Years
Max Age75 Years
Start Date2019-09-19
Completion2027-07-01
Interventions
Polyethylene glycol (PEG)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Current strategies for peripheral nerve repair are severely limited. Even with current techniques, it can take months for regenerating axons to reach denervated target tissues when injuries are proximally located. This inability to rapidly restore the loss of function after axonal injury continues to produce poor clinical outcomes. The investigators propose testing the efficacy and safety of a combination therapy: polyethylene glycol (PEG) assisted axonal fusion technique to repair peripheral nerve injuries in humans.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of a Sunderland Class 5 traumatic neuropathy (transection injury) of a digital nerve in the upper extremity * candidates for immediate operative repair (Arm 1); * injury proceeding repair no longer than 72 hours; and * repair within 48 hours of injury that require nerve grafting; * N0 significant medical comorbidities precluding immediate repair; * willing to comply with all aspects of the treatment and evaluation schedule over a 12 months period. We plan to include subjects who have peripheral nerve injuries that are complicated by significant vascular or orthopedic damage. Exclusion Criteria: * Patients will be excluded from enrollment if their injuries exhibit gross contamination, in circumstances where soft tissue coverage is inadequate, or when staged repair is planned. * We will also exclude patients that are diabetic, have been diagnosed with a neuromuscular disease, or are undergoing chemotherapy, radiation therapy, or other treatments known to a

Related Trials